JP2011252167A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011252167A5 JP2011252167A5 JP2011180530A JP2011180530A JP2011252167A5 JP 2011252167 A5 JP2011252167 A5 JP 2011252167A5 JP 2011180530 A JP2011180530 A JP 2011180530A JP 2011180530 A JP2011180530 A JP 2011180530A JP 2011252167 A5 JP2011252167 A5 JP 2011252167A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- aryl group
- nhcor
- halogen atom
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 15
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 125000005843 halogen group Chemical group 0.000 claims description 9
- 229920000642 polymer Polymers 0.000 claims description 7
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 125000000468 ketone group Chemical group 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 5
- 125000003107 substituted aryl group Chemical group 0.000 claims description 5
- 125000004185 ester group Chemical group 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 125000003277 amino group Chemical group 0.000 claims description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 3
- 125000005647 linker group Chemical group 0.000 claims description 2
- 229920001515 polyalkylene glycol Polymers 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- ICGQLNMKJVHCIR-UHFFFAOYSA-N 1,3,2-dioxazetidin-4-one Chemical compound O=C1ONO1 ICGQLNMKJVHCIR-UHFFFAOYSA-N 0.000 description 2
- PYSRRFNXTXNWCD-UHFFFAOYSA-N 3-(2-phenylethenyl)furan-2,5-dione Chemical compound O=C1OC(=O)C(C=CC=2C=CC=CC=2)=C1 PYSRRFNXTXNWCD-UHFFFAOYSA-N 0.000 description 2
- 229930182556 Polyacetal Natural products 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920001710 Polyorthoester Polymers 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 229920000147 Styrene maleic anhydride Polymers 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- DQJJMWZRDSGUJP-UHFFFAOYSA-N ethenoxyethene;furan-2,5-dione Chemical compound C=COC=C.O=C1OC(=O)C=C1 DQJJMWZRDSGUJP-UHFFFAOYSA-N 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 229920000765 poly(2-oxazolines) Polymers 0.000 description 2
- 239000002745 poly(ortho ester) Substances 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- -1 polymethacrylamide Polymers 0.000 description 2
- 229920000193 polymethacrylate Polymers 0.000 description 2
- 229920006324 polyoxymethylene Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0813339A GB0813339D0 (en) | 2008-07-21 | 2008-07-21 | Novel reagents and method for conjugating biological molecules |
| GB0813339.9 | 2008-07-21 | ||
| GB0905762A GB0905762D0 (en) | 2009-04-02 | 2009-04-02 | Novel reagents and method for conjugating biological molecules |
| GB0905762.1 | 2009-04-02 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011519228A Division JP5622117B2 (ja) | 2008-07-21 | 2009-07-17 | 生体分子を接合するための新規な試薬及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011252167A JP2011252167A (ja) | 2011-12-15 |
| JP2011252167A5 true JP2011252167A5 (enExample) | 2012-08-30 |
| JP5626655B2 JP5626655B2 (ja) | 2014-11-19 |
Family
ID=41226122
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011519228A Expired - Fee Related JP5622117B2 (ja) | 2008-07-21 | 2009-07-17 | 生体分子を接合するための新規な試薬及び方法 |
| JP2011180530A Expired - Fee Related JP5626655B2 (ja) | 2008-07-21 | 2011-08-22 | 生体分子を接合するための新規な試薬及び方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011519228A Expired - Fee Related JP5622117B2 (ja) | 2008-07-21 | 2009-07-17 | 生体分子を接合するための新規な試薬及び方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US8969626B2 (enExample) |
| EP (2) | EP2326349B1 (enExample) |
| JP (2) | JP5622117B2 (enExample) |
| KR (1) | KR101763559B1 (enExample) |
| CN (1) | CN102099058B (enExample) |
| AU (1) | AU2009275358C1 (enExample) |
| DK (2) | DK2326349T3 (enExample) |
| ES (2) | ES2560807T3 (enExample) |
| PL (1) | PL2326349T3 (enExample) |
| WO (1) | WO2010010324A1 (enExample) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0316294D0 (en) | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
| AU2007333049B2 (en) | 2006-12-15 | 2014-02-20 | Takeda Pharmaceutical Company Limited | Factor VIIa-(poly)sialic acid conjugate having prolonged in vivo half-life |
| WO2010010324A1 (en) | 2008-07-21 | 2010-01-28 | Polytherics Limited | Novel reagents and method for conjugating biological molecules |
| US9005598B2 (en) | 2009-03-04 | 2015-04-14 | Polytherics Limited | Conjugated proteins and peptides |
| US8809501B2 (en) | 2009-07-27 | 2014-08-19 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| RU2744370C2 (ru) | 2009-07-27 | 2021-03-05 | Баксалта Инкорпорейтед | Конъюгаты белков свертывания крови |
| WO2011012850A2 (en) | 2009-07-27 | 2011-02-03 | Lipoxen Technologies Limited | Glycopolysialylation of non-blood coagulation proteins |
| US8642737B2 (en) | 2010-07-26 | 2014-02-04 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| US8637640B2 (en) | 2009-07-27 | 2014-01-28 | Baxter International Inc. | Blood coagulation protein conjugates |
| GB201007357D0 (en) | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIII |
| GB201007356D0 (en) | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIIa |
| WO2012039602A1 (en) * | 2010-09-21 | 2012-03-29 | Universiteit Utrecht Holding B.V. | Tunable, biodegradable linker molecules for transient conjugation of components in drug delivery systems, and drug delivery systems prepared therewith |
| PL2654794T3 (pl) | 2010-12-22 | 2020-07-27 | Baxalta GmbH | Materiały i sposoby sprzęgania rozpuszczalnej w wodzie pochodnej kwasu tłuszczowego z białkiem |
| EP2714093A1 (en) * | 2011-05-27 | 2014-04-09 | Baxter International Inc. | Therapeutic proteins with increased half-life and methods of preparing same |
| JP5841768B2 (ja) * | 2011-08-05 | 2016-01-13 | 花王株式会社 | 脂肪蓄積抑制剤 |
| GB201910190D0 (en) | 2012-04-16 | 2019-08-28 | Cantab Biopharmaceuticals Patents Ltd | Optimised subsutaneous therapeutic agents |
| GB201210770D0 (en) * | 2012-06-18 | 2012-08-01 | Polytherics Ltd | Novel conjugation reagents |
| US9650331B2 (en) | 2012-06-18 | 2017-05-16 | Polytherics Limited | Conjugation reagents |
| US9522876B2 (en) | 2013-03-15 | 2016-12-20 | Zymeworks Inc. | Cytotoxic and anti-mitotic compounds, and methods of using the same |
| EP3964237B1 (en) | 2013-03-15 | 2026-02-18 | Regeneron Pharmaceuticals, Inc. | Biologically active molecules, conjugates thereof, and therapeutic uses |
| KR102252925B1 (ko) | 2013-08-26 | 2021-05-18 | 리제너론 파마슈티칼스 인코포레이티드 | 마크롤라이드 디아스테레오머를 포함하는 약제학적 조성물, 이의 합성 방법 및 치료학적 용도 |
| ES2916722T3 (es) | 2013-12-27 | 2022-07-05 | Zymeworks Inc | Sistemas de enlace que contienen sulfonamida para conjugados de fármacos |
| MY178160A (en) | 2014-03-11 | 2020-10-06 | Regeneron Pharma | Anti-egfrviii antibodies and uses thereof |
| EP3194421B1 (en) | 2014-09-17 | 2021-11-03 | Zymeworks Inc. | Cytotoxic and anti-mitotic compounds, and methods of using the same |
| WO2016059377A1 (en) | 2014-10-14 | 2016-04-21 | Polytherics Limited | Process for the conjugation of a peptide or protein with a reagent comprising a leaving group including a portion of peg |
| KR20240142591A (ko) | 2015-03-27 | 2024-09-30 | 리제너론 파아마슈티컬스, 인크. | 메이탄시노이드 유도체, 이의 컨주게이트, 및 사용 방법 |
| MY189159A (en) | 2015-07-06 | 2022-01-29 | Regeneron Pharma | Multispecific antigen-binding molecules and uses thereof |
| CN108602890A (zh) | 2015-12-11 | 2018-09-28 | 瑞泽恩制药公司 | 用于减少或预防对egfr和/或erbb3阻滞剂具有抗性的肿瘤生长的方法 |
| MY198605A (en) | 2016-01-25 | 2023-09-08 | Regeneron Pharma | Maytansinoid derivatives conjugates thereof, and methods of use |
| US10821160B2 (en) * | 2016-03-01 | 2020-11-03 | The Board Of Trustees Of The University Of Illinois | L-asparaginase variants and fusion proteins with reduced L-glutaminase activity and enhanced stability |
| WO2017190079A1 (en) | 2016-04-28 | 2017-11-02 | Regeneron Pharmaceuticals, Inc. | Methods of making multispecific antigen-binding molecules |
| JP2019524687A (ja) | 2016-07-01 | 2019-09-05 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | 抗体薬物複合体およびこれを用いた治療方法 |
| MA46417A (fr) | 2016-09-23 | 2019-07-31 | Regeneron Pharma | Anticorps anti-steap2, conjugués anticorps-médicament, et molécules bispécifiques de liaison à l'antigène qui se lient à steap2 et cd3, et leurs utilisations |
| US10738130B2 (en) | 2016-09-23 | 2020-08-11 | Regeneron Pharmaceuticals, Inc. | Bispecific antigen-binding molecules that bind MUC16 and CD3, and compositions thereof |
| KR20250114431A (ko) | 2016-11-08 | 2025-07-29 | 리제너론 파마슈티칼스 인코포레이티드 | 스테로이드 및 이의 단백질-접합체 |
| TWI782930B (zh) | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法 |
| KR20200007905A (ko) | 2017-05-18 | 2020-01-22 | 리제너론 파마슈티칼스 인코포레이티드 | 사이클로덱스트린 단백질 약물 접합체 |
| ES3065816T3 (en) | 2017-06-07 | 2026-05-08 | Regeneron Pharma | Compositions and methods for internalizing enzymes |
| IL313068A (en) | 2017-11-07 | 2024-07-01 | Regeneron Pharma | Hydrophilic linkers for antibody drug conjugates |
| IL275757B2 (en) | 2018-01-08 | 2025-08-01 | Regeneron Pharma | Steroids and antibody-conjugates thereof |
| CN112074538B (zh) | 2018-04-30 | 2024-10-18 | 瑞泽恩制药公司 | 结合her2和/或aplp2的抗体和双特异性抗原结合分子、其缀合物和用途 |
| MX2020011546A (es) | 2018-05-09 | 2021-01-29 | Regeneron Pharma | Anticuerpos anti-msr1 y metodos de uso de los mismos. |
| BR112020023145A2 (pt) | 2018-05-17 | 2021-02-02 | Regeneron Pharmaceuticals, Inc. | anticorpo anti-cd63 ou fragmento de ligação ao antígeno do mesmo, molécula de ligação ao antígeno biespecífica, proteína terapêutica de múltiplos domínios, polinucleotídeo composição farmacêutica, e, composto |
| CA3123607A1 (en) | 2018-12-21 | 2020-06-25 | Regeneron Pharmaceuticals, Inc. | Rifamycin analogs and antibody-drug conjugates thereof |
| MX2021010114A (es) | 2019-02-21 | 2021-12-10 | Regeneron Pharma | Métodos para tratar el cáncer ocular mediante el uso de anticuerpos anti-met y moléculas de unión a antígeno bispecíficas que se unen a met. |
| JP7750828B2 (ja) | 2019-09-16 | 2025-10-07 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 免疫ｐｅｔ撮像のための放射標識されたｍｅｔ結合タンパク質 |
| US11814428B2 (en) | 2019-09-19 | 2023-11-14 | Regeneron Pharmaceuticals, Inc. | Anti-PTCRA antibody-drug conjugates and uses thereof |
| IL295312A (en) | 2020-02-28 | 2022-10-01 | Regeneron Pharma | Bispecific antigen binding molecules that bind her2, and methods of use thereof |
| JP2023521885A (ja) | 2020-04-16 | 2023-05-25 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ディールス－アルダーコンジュゲーション方法 |
| US12605459B2 (en) | 2020-07-13 | 2026-04-21 | Regeneron Pharmaceuticals, Inc. | Protein-drug conjugates comprising camptothecin analogs and methods of use thereof |
| MX2023002974A (es) | 2020-09-14 | 2023-05-25 | Regeneron Pharma | Conjugados de anticuerpo-farmaco que comprenden peptidomimeticos glp1 y usos de los mismos. |
| CA3190569A1 (en) | 2020-10-22 | 2022-04-28 | Christopher Daly | Anti-fgfr2 antibodies and methods of use thereof |
| CN113461929B (zh) * | 2021-07-13 | 2023-04-21 | 浙江倍合德制药有限公司 | 一种tpgs系列产品的精制提纯方法 |
| CN118829449A (zh) | 2022-01-12 | 2024-10-22 | 瑞泽恩制药公司 | 与蛋白中的谷氨酰胺残基缀合的喜树碱类似物及其用途 |
| AU2023231305A1 (en) | 2022-03-11 | 2024-09-12 | Regeneron Pharmaceuticals, Inc. | Anti-GLP1r antibody-tethered drug conjugates comprising GLP1 peptidomimetics and uses thereof |
| KR20250069711A (ko) | 2022-07-21 | 2025-05-19 | 파이어플라이 바이오, 인크. | 글루코코르티코이드 수용체 작용제 및 이의 접합체 |
| CN120752059A (zh) | 2022-12-21 | 2025-10-03 | 瑞泽恩制药公司 | 用于adc缀合的拓扑异构酶i抑制剂的前药及其使用方法 |
| CN121039163A (zh) | 2023-05-02 | 2025-11-28 | 瑞泽恩制药公司 | 抗人m-钙粘蛋白（cdh15）抗体、缀合物及其用于将遗传有效负载递送至肌肉细胞的用途 |
| IL325400A (en) | 2023-07-10 | 2026-02-01 | Regeneron Pharma | Anti-human CACNG1 antibody-drug conjugates and their uses |
| US20250171516A1 (en) | 2023-11-03 | 2025-05-29 | Regeneron Pharmaceuticals, Inc. | Peptide acids as a glp1r agonist and antibody-drug conjugates thereof |
| WO2026020031A2 (en) | 2024-07-18 | 2026-01-22 | Novarock Biotherapeutics, Ltd. | Cdh17 antibodies and uses thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US147443A (en) * | 1874-02-10 | Improvement in lamp-extinguishers | ||
| US6552170B1 (en) * | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
| US5414135A (en) | 1991-12-30 | 1995-05-09 | Sterling Winthrop Inc. | Vinyl sulfone coupling of polyoxyalkylenes to proteins |
| US5446090A (en) * | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| US5877224A (en) | 1995-07-28 | 1999-03-02 | Rutgers, The State University Of New Jersey | Polymeric drug formulations |
| GB9713979D0 (en) * | 1997-07-03 | 1997-09-10 | Univ Nottingham | Method for attaching peg to macromolecules |
| US6958212B1 (en) * | 1999-02-01 | 2005-10-25 | Eidgenossische Technische Hochschule Zurich | Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds |
| US6828412B1 (en) | 1999-09-03 | 2004-12-07 | School Of Pharmacy, University Of London | Degradable polymers |
| US6803438B1 (en) | 1999-09-08 | 2004-10-12 | Polytherics Limited | Uniform molecular weight polymers |
| JP4490290B2 (ja) | 2002-12-31 | 2010-06-23 | ネクター セラピューティクス アラバマ，コーポレイション | 加水分解安定性マレイミド末端ポリマー |
| JP4009721B2 (ja) * | 2003-05-23 | 2007-11-21 | 独立行政法人産業技術総合研究所 | イオン結合性ポリマー含有基板、該基板を含有する検出用センサー及び病原菌又は病原菌が生産する毒素の検出方法 |
| GB0316294D0 (en) * | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
| EP1828244A2 (en) | 2004-12-22 | 2007-09-05 | Kuros Biosurgery AG | Michael-type addition reaction functionalised peg hydrogels with factor xiiia incorporated biofactors |
| DK2209494T3 (en) | 2007-10-09 | 2016-10-03 | Polytherics Ltd | New conjugated proteins and peptides |
| WO2010010324A1 (en) | 2008-07-21 | 2010-01-28 | Polytherics Limited | Novel reagents and method for conjugating biological molecules |
| US9005598B2 (en) * | 2009-03-04 | 2015-04-14 | Polytherics Limited | Conjugated proteins and peptides |
| GB0912485D0 (en) | 2009-07-17 | 2009-08-26 | Polytherics Ltd | Improved conjugation method |
-
2009
- 2009-07-17 WO PCT/GB2009/001764 patent/WO2010010324A1/en not_active Ceased
- 2009-07-17 DK DK09784718.0T patent/DK2326349T3/en active
- 2009-07-17 EP EP09784718.0A patent/EP2326349B1/en not_active Not-in-force
- 2009-07-17 ES ES11171786.4T patent/ES2560807T3/es active Active
- 2009-07-17 ES ES09784718.0T patent/ES2536882T3/es active Active
- 2009-07-17 US US13/055,455 patent/US8969626B2/en not_active Expired - Fee Related
- 2009-07-17 CN CN200980128495.3A patent/CN102099058B/zh not_active Expired - Fee Related
- 2009-07-17 KR KR1020117003833A patent/KR101763559B1/ko not_active Expired - Fee Related
- 2009-07-17 DK DK11171786.4T patent/DK2374481T3/en active
- 2009-07-17 PL PL09784718T patent/PL2326349T3/pl unknown
- 2009-07-17 JP JP2011519228A patent/JP5622117B2/ja not_active Expired - Fee Related
- 2009-07-17 EP EP11171786.4A patent/EP2374481B1/en not_active Not-in-force
- 2009-07-17 AU AU2009275358A patent/AU2009275358C1/en not_active Ceased
-
2011
- 2011-07-01 US US13/175,820 patent/US8618333B2/en not_active Expired - Fee Related
- 2011-08-22 JP JP2011180530A patent/JP5626655B2/ja not_active Expired - Fee Related
-
2013
- 2013-11-21 US US14/086,702 patent/US9896412B2/en not_active Expired - Fee Related
-
2015
- 2015-02-04 US US14/614,152 patent/US20150148544A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021532162A5 (enExample) | ||
| JP2021533135A5 (enExample) | ||
| EP2374481B1 (en) | Novel reagents and method for conjugating biological molecules | |
| HRP20210562T1 (hr) | Karbohidratni ligandi koji se vežu na igm antitijela koja djeluju protiv glikoproteina povezanog s mijelinom | |
| IL268756A (en) | Piperazine-2,5-dione derivatives, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments | |
| JP2008535954A5 (enExample) | ||
| JP2022510313A5 (enExample) | ||
| JP2014527974A5 (enExample) | ||
| JP2008509166A5 (enExample) | ||
| JP2011528654A5 (enExample) | ||
| JP2017528467A5 (enExample) | ||
| JP2012523457A5 (enExample) | ||
| JP2017511305A5 (enExample) | ||
| RU2009128982A (ru) | Пиразолопиримидиновые соединения | |
| CA2653941A1 (en) | Substituted amino purine derivatives and uses thereof | |
| JP2019532928A5 (enExample) | ||
| NZ701290A (en) | Pyrrolobenzodiazepines | |
| JP2010509366A5 (enExample) | ||
| RU2007115075A (ru) | Новый блок-сополимер, мицеллярный препарат и противораковое средство, включающее мицеллярный препарат в качестве активного ингредиента | |
| CA2438646A1 (en) | Pyrimidine derivatives for inhibition of cell-proliferation | |
| JP5711378B2 (ja) | ブロック共重合体の製造方法 | |
| ME02675B (me) | Novi derivati cikloheksilamina sa aktivnostima beta2 adrenergijskog agonista i m3 muscarinskog antagonista | |
| JP2013510181A5 (enExample) | ||
| JP2005500325A5 (enExample) | ||
| RU2012124266A (ru) | Хелаты марганца и их применение в качестве контрастных агентов в магнитно-резонансной визуализации (mpb) |